Role of Bromocriptine in Peripartum Cardiomyopathy
Not Applicable
- Conditions
- Health Condition 1: O268- Other specified pregnancy relatedconditions
- Registration Number
- CTRI/2023/09/057654
- Lead Sponsor
- ICMR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Women who will be diagnosed as having PPCM with ejection fraction =35%
Exclusion Criteria
Clinical conditions other than cardiomyopathy that could increase plasma levels of inflammatory markers such as sepsis, autoimmune disease, or HIV positivity
Any thrombogenic condition
Severe peptic ulcer disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in ejection fraction <br/ ><br>Full recovery (ejection fraction =50%) <br/ ><br>Timepoint: Improvement in ejection fraction at 8 weeks <br/ ><br>Full recovery (ejection fraction =50%) at 6 months <br/ ><br>
- Secondary Outcome Measures
Name Time Method evels of prolactin and cardiac biomarkers <br/ ><br>Growth patterns of the infantsTimepoint: 8 weeks and 6 months